Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization

Table 4 Comparison of the area under the curve between inflammation-based prognostic scores and staging systems

Period	AUC	95%CI	P value
6-mo
GPS	0.702	0.630-0.773	< 0.001
mGPS	0.699	0.627-0.770	< 0.001
PI	0.681	0.609-0.754	< 0.001
NLR	0.582	0.505-0.659	0.410
PNI	0.561	0.482-0.640	0.126
PLR	0.531	0.385-0.629	0.436
TNM	0.649	0.575-0.723	< 0.001
BCLC	0.635	0.559-0.712	0.001
CLIP	0.656	0.582-0.730	< 0.001
12-mo
GPS	0.676	0.604-0.747	< 0.001
mGPS	0.665	0.592-0.738	< 0.001
PI	0.652	0.577-0.726	< 0.001
NLR	0.590	0.513-0.667	0.024
PNI	0.527	0.450-0.605	0.495
PLR	0.537	0.460-0.615	0.346
TNM	0.651	0.576-0.725	< 0.001
BCLC	0.656	0.584-0.729	< 0.001
CLIP	0.711	0.644-0.778	< 0.001
24-mo
GPS	0.687	0.601-0.772	< 0.001
mGPS	0.684	0.601-0.767	< 0.001
PI	0.682	0.599-0.766	< 0.001
NLR	0.593	0.498-0.688	0.063
PNI	0.512	0.415-0.609	0.808
PLR	0.554	0.457-0.652	0.279
TNM	0.706	0.621-0.791	< 0.001
BCLC	0.656	0.572-0.741	0.002
CLIP	0.721	0.644-0.797	< 0.001

BCLC: Barcelona Clinic Liver Cancer; CI: Confidence interval; CLIP: Cancer of the Liver Italian Program; GPS: Glasgow Prognostic Score; mGPS: Modifed Glasgow Prognostic Score; NLR: Neutrophil lymphocyte ratio; PI: Prognostic index; PLR: Platelet-lymphocyte ratio; PNI: Prognostic nutritional index; TNM: Tumor-node-metastasis.